Literature DB >> 16097853

Extended-release carbamazepine capsules: a viewpoint.

Philip B Mitchell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16097853     DOI： 10.2165/00023210-200519080-00008

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  5 in total

1.  Therapeutic effects of carbamazepine in affective illness: a preliminary report.

Authors:  J C Ballenger; R M Post
Journal:  Commun Psychopharmacol       Date:  1978

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  The expanding pharmacopoeia for bipolar disorder.

Authors:  Philip B Mitchell; Gin S Malhi
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

4.  Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey.

Authors:  P B Mitchell; T Slade; G Andrews
Journal:  Psychol Med       Date:  2004-07       Impact factor: 7.723

5.  Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report.

Authors:  T Okuma; A Kishimoto; K Inoue; H Matsumoto; A Ogura
Journal:  Folia Psychiatr Neurol Jpn       Date:  1973
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.